# Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

> **NCT02971033** · PHASE2 · TERMINATED · sponsor: **VA Office of Research and Development** · enrollment: 2 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** 20mg ezetimibe
- **DRUG:** Placebo
- **DRUG:** 40mg ezetimibe

## Key facts

- **NCT ID:** NCT02971033
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-16
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study Funding ended
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971033, "Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02971033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*